■白细胞介素-6(IL-6),高炎性免疫反应的生物标志物,可用于确定需要重症监护的多器官受累患者2019年冠状病毒病(COVID-19)的严重程度。我们研究的目的是了解血液透析的效用,不仅在减轻肾脏负担方面,而且还可以通过解决COVID细胞因子风暴综合征来改善结果。
■在这个前景中,观察性研究,入住COVID重症监护病房(ICU)病房的126例患者因急性肾损伤(AKI)接受了血液透析治疗。评估患者的常规基线血液参数。在所有患者的透析前和存活患者的出院当天测量IL-6。
■在总共126名患者中,79人是幸存者,47人是非幸存者。在非幸存者中,大多数年龄较大(P=0.009)。两组的男性比例均较高(幸存者和非幸存者分别为78.72%和55.69%,分别)。与幸存者相比,非幸存者的平均中性粒细胞淋巴细胞比率(NLR)和D-二聚体水平显着升高(P<0.001)。平均血清尿素,肌酐,非存活者中IL-6水平显著升高(P<0.001)。幸存者接受的平均血液透析次数较高。存活者的deltaIL-6和delta血清肌酐曲线呈显著正相关(r=0.819,P<0.001)。
■我们的研究将IL-6确定为COVIDICUAKI患者的不良预后预测因子。它还强调使用血液透析作为一种具有成本效益的挽救生命的治疗介入方式,不仅可以改善肾脏预后,而且还通过降低IL-6水平来抑制细胞因子风暴。
UNASSIGNED: Interleukin-6 (IL-6), a biomarker of hyperinflammatory immune response, can be used to determine the severity of coronavirus disease 2019 (COVID-19) in patients with multi-organ involvement requiring critical care. The aim of our study is to understand the utility of hemodialysis, not only in terms of reducing renal burden, but also improving the outcome by tackling the COVID cytokine storm syndrome.
UNASSIGNED: In this prospective, observational study, 126 patients admitted to the COVID intensive care unit (ICU) wards were treated with hemodialysis for acute kidney injury (AKI). Patients\' routine baseline blood parameters were evaluated. IL-6 was measured predialysis in all patients and on the day of discharge in the patients who survived.
UNASSIGNED: Out of total 126 patients, 79 were survivors and 47 were nonsurvivors. Among nonsurvivors, majority were older (P = 0.009). Both the groups had a higher percentage of males (78.72% and 55.69% in survivors and nonsurvivors, respectively). Mean neutrophil lymphocyte ratio (NLR) and D-dimer level were significantly higher in nonsurvivors compared to survivors (P < 0.001). Mean serum urea, creatinine, and IL-6 levels were significantly greater in nonsurvivors (P < 0.001). Mean number of hemodialysis sessions received by survivors was higher. The curve between delta IL-6 and delta serum creatinine for survivors showed a significant positive association (r = 0.819, P < 0.001).
UNASSIGNED: Our study establishes IL-6 as a poor outcome predictor in COVID ICU patients with AKI. It also emphasizes the use of hemodialysis as a cost-effective lifesaving therapeutic interventional modality to not only improve the renal outcome, but also curb the cytokine storm by reducing IL-6 levels.